此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy

2019年10月9日 更新者:Paulo Marcelo Gehn Hoff、Instituto do Cancer do Estado de São Paulo

A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy

The humanized monoclonal antibody against Lewis Y antigen (Hu3S193) has been demonstrated to be safe in previous studies and has also been indicated as potential intervention in breast cancer. The study of this new agent in advanced breast cancer may contribute to the development of new strategies for patients that progressed after hormonal treatment.

研究概览

地位

终止

条件

干预/治疗

详细说明

This is a national study, open label, single arm, phase II study which will be conducted in seven centers in Brazil. The study will be coordinated by the INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO in collaboration with RECEPTA Biopharma. The study is funded by the CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO (CNPq). Before any procedure relating to the study, patients must read and sign the informed consent (IC). The inclusion of patients begin immediately after regulatory approval and is expected to end after reaching the number of patients. The follow-up term will last at least 24 months for each patient included, unless limited by death, loss to follow up or withdrawal of informed consent. A total of 60 patients will be recruited in this study. The eligible patients must be 18 or older, confirmed diagnosis of breast cancer with locally advanced or metastatic progression after one or two lines of previous hormone treatment, confirmation of Lewis antigen expression -as assessed by central laboratory, measurable or evaluable disease and adequate organ function. Patients will receive weekly intravenous doses of the antibody Hu3S193 until disease progression, unacceptable toxicity, withdrawal of consent or the investigator's decision, whichever occurs first. The study's primary endpoint is the clinical benefit rate.

研究类型

介入性

注册 (实际的)

23

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Goias、巴西
        • Universidade Federal de Goias
      • Rio de Janeiro、巴西
        • Instituto Nacional do Cancer
      • Sao Paulo、巴西、01246-000
        • Instituto do Cancer do Estado de Sao Paulo
      • Sao Paulo、巴西
        • Hospital Sirio Libanes
    • Ceará
      • Fortaleza、Ceará、巴西
        • Universidade Federal Do Ceara
    • RIO Grande DO SUL
      • Porto Alegre、RIO Grande DO SUL、巴西
        • Pontificia Universidade Católica do Rio Grande do Sul
    • SÃO Paulo
      • Barretos、SÃO Paulo、巴西
        • Hospital do Cancer de Barretos

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Diagnosis of breast cancer with locally advanced or metastatic (stages IIIB, IIIC or IV according to TNM classification), confirmed histologically with no intention to curative treatment by radiotherapy or surgery;
  • Clinical or radiological progression after one or two lines of previous hormone treatment, including adjuvant treatment;
  • Positive for ER and / or PR expression documented by IHC;
  • Confirmed expression of Lewis Y antigen by IHC;
  • Presenting the performance status of 0 or 1 according to Eastern Cooperative Oncology Group (ECOG);
  • Have a measurable or evaluable disease by Response of Evaluation Criteria in Solid Tumors (RECIST);
  • Adequate organ function, assessed by laboratory tests obtained at least 2 weeks before the first day of treatment and within the following parameters:

absolute neutrophil count ≥ 1.5 x 109 / L; platelet count ≥ 100 x 109 / L; serum bilirubin ≤ 2.0 mg / dL; AST/ALT ≤ 2.5 x upper limit of normal; serum creatinine ≤ 2.0 mg / dL;

  • Expected survival > 12 weeks;
  • In patients with childbearing potential: Negative pregnancy confirmed by test done 21 days before the date of study treatment initiation;
  • Willingness and ability to comply with the protocol for the duration of the study.

Exclusion Criteria:

  • Patients subjected previously to more than two lines of hormonal therapy, including adjuvant treatment;
  • Presenting the amplification or overexpression of HER-2;
  • Systemic corticosteroids or immunosuppressive agents used concomitantly with the study or have used systemic corticosteroids or immunosuppressants in the last 14 days before the first dose of the investigational drug;
  • Visceral metastatic disease with life-threatening (as defined by extensive liver involvement), or symptomatic pulmonary lymphangitic carcinomatosis or any degree of cerebral or leptomeningeal involvement;
  • Previous or current history of clinically significant cardiac disease (class III or IV according to New York Heart Association);
  • Clinically significant arrhythmia;
  • History of myocardial infarction within the last 6 months;
  • Previous or current history of other severe diseases (eg, severe ascites requiring repeated drainage, active infections requiring antibiotics, bleeding, inflammatory bowel disease or chronic diseases that may interfere with obtaining accurate results of the study);
  • Previous chemotherapy for metastatic disease (adjuvant chemotherapy is acceptable, if more than four weeks between its completion and inclusion in the study;
  • Radiotherapy within 4 weeks before inclusion in the study or with no recovery from the toxic effects of radiotherapy when done up to 6 weeks before inclusion in the study, except for palliative radiotherapy for bone metastases involving <25 % bone marrow;
  • Treatment with biological agents, immunotherapy or surgery within 4 weeks before inclusion in the study or with no recovery from the toxic effects of these treatments when made until six weeks prior to study entry (prior treatment with bisphosphonates is allowed, it can be continued after inclusion in the study);
  • Any investigational agent treatment within 12 months prior to study entry, unless the investigator considers that the participation in the study may benefit the patient;
  • Previous or current history of another type of tumor, excluding skin cancer, melanoma, in situ cervix carcinoma or in situ ductal carcinoma or lobular breast if properly treated;
  • Uncontrolled hypercalcemia (defined as total calcium> 11.5 mg / dL)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Hu3S193
Single arm
Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete response, partial response or stable disease.
大体时间:more than 24 weeks
The primary efficacy analysis will be done through the clinical benefit rate, as defined by the proportion of patients achieving best response, complete response, partial response or stable disease for more than 24 weeks
more than 24 weeks

次要结果测量

结果测量
措施说明
大体时间
Response rate
大体时间:24 weeks after patient discontinuation (at minimum)
from inclusion until disease progression or death
24 weeks after patient discontinuation (at minimum)
Non progression rate
大体时间:24 weeks after patient discontinuation (at minimum)
From patient inclusion until disease progression or death - evaluated radiologically by CT
24 weeks after patient discontinuation (at minimum)
Overall survival
大体时间:24 weeks after patient discontinuation (at minimum) or until death
until death
24 weeks after patient discontinuation (at minimum) or until death
Progression free survival
大体时间:until disease progression or 24 weeks after patient discontinuation (at minimum)
Evaluated radiologically by CT
until disease progression or 24 weeks after patient discontinuation (at minimum)
Assessment of any sign, symptom or undesirable medical condition that occurs after the first administration of the investigational agent
大体时间:Until disease progression or 30 days after patient discontinuation
Until disease progression or 30 days after patient discontinuation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:PAULO MG HOFF, MD Professor、Instituto do Cancer do Estado de Sao Paulo
  • 研究主任:SERGIO V SERRANO, MD、Hospital do Cancer de Barretos

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年11月1日

初级完成 (实际的)

2015年10月1日

研究完成 (实际的)

2018年5月25日

研究注册日期

首次提交

2011年5月25日

首先提交符合 QC 标准的

2011年6月8日

首次发布 (估计)

2011年6月9日

研究记录更新

最后更新发布 (实际的)

2019年10月11日

上次提交的符合 QC 标准的更新

2019年10月9日

最后验证

2019年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 52/2009

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Hu3S193的临床试验

3
订阅